These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15710171)

  • 1. 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice.
    Innocenti F; Danesi R; Bocci G; Natale G; Del Tacca M
    Toxicol Appl Pharmacol; 2005 Mar; 203(2):106-13. PubMed ID: 15710171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography-tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity.
    Serdar MA; Sertoğlu E; Uyanık M; Tapan S; Akın O; Cihan M
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):525-9. PubMed ID: 21107571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats.
    Tateishi T; Watanabe M; Nakura H; Tanaka M; Kumai T; Sakata SF; Tamaki N; Ogura K; Nishiyama T; Watabe T; Kobayashi S
    Drug Metab Dispos; 1999 Jun; 27(6):651-4. PubMed ID: 10348793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats.
    Nagata M; Hidaka Y; Hatakeyama K; Kawano Y; Iwakiri T; Okumura M; Arimori K
    Biopharm Drug Dispos; 2011 Mar; 32(2):126-30. PubMed ID: 21341281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.
    Li LH; Dong H; Zhao F; Tang J; Chen X; Ding J; Men HT; Luo WX; Du Y; Ge J; Tan BX; Cao D; Liu JY
    Eur J Cancer; 2013 May; 49(7):1752-60. PubMed ID: 23313143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice.
    Jin Y; Li J; Rong LF; Lü XW; Huang Y; Xu SY
    Acta Pharmacol Sin; 2005 Feb; 26(2):250-6. PubMed ID: 15663907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil.
    Spector T; Cao S; Rustum YM; Harrington JA; Porter DJ
    Cancer Res; 1995 Mar; 55(6):1239-41. PubMed ID: 7882316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parenteral nutrition decreases hepatic dihydropyrimidine dehydrogenase activity and modulates catabolism of 5-fluorouracil in rats.
    Taniguchi M; Yano M; Tsujinaka T; Ogawa A; Morita S; Kaneko K; Akiyama Y; Miki H; Monden M
    In Vivo; 2003; 17(3):219-23. PubMed ID: 12929570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
    Bocci G; Danesi R; Allegrini G; Innocenti F; Di Paolo A; Falcone A; Conte PF; Del Tacca M
    Eur J Clin Pharmacol; 2002 Dec; 58(9):593-5. PubMed ID: 12602342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assay method for uracil, dihydrouracil, 5-fluorouracil and 5-fluoro-5, 6-dihydrouracil by high-performance liquid chromatography].
    Nakamura A; Kikuchi K; Ohishi T; Masuike T
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):381-6. PubMed ID: 15045945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients.
    Casale F; Canaparo R; Serpe L; Muntoni E; Pepa CD; Costa M; Mairone L; Zara GP; Fornari G; Eandi M
    Pharmacol Res; 2004 Aug; 50(2):173-9. PubMed ID: 15177306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer.
    Aboagye EO; Saleem A; Cunningham VJ; Osman S; Price PM
    Cancer Res; 2001 Jul; 61(13):4937-41. PubMed ID: 11431319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined determination of urine uracil levels and plasma 5-FU clearance for a simple order-made treatment with anticancer agents of FU derivative].
    Morimoto S; Mishima H; Tsujinaka T; Kawato N; Shono Y; Tsuji T; Tabuse K; Nakata I; Saito M; Uenaka K
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):89-94. PubMed ID: 12557710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
    Wang GP; Guan YS; Jin XR; Jiang SS; Lu ZJ; Wu Y; Li Y; Li M; Luo F
    J Gastroenterol Hepatol; 2010 May; 25(5):985-90. PubMed ID: 20546454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
    Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
    Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
    Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dose, administration time and route and hepatic function-dependent metabolism of 5-FU in mice].
    Okamoto M; Takao A; Fujita H
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3483-90. PubMed ID: 3789759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.